{"analyses":[{"ciLowerLimit":"0.42","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.68","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.53","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the Confidence Interval is not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"40.0","upperLimit":"NA","value":"46.7"},{"comment":"The Median time to progression was not reached in this arm. Consequently, the lower and upper limit of the Confidence Interval is not available due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"444"},{"groupId":"OG001","value":"442"}],"units":"Participants"}],"description":"Progression Free Survival (PFS) post completion of maintenance therapy is defined as the duration from the date of second randomization to either progressive disease (according to the IMWG criteria specified in the protocol), or death, whichever occurs first (=all these considered as events) at the completion of Maintenance therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients randomized to the Observation group at rando 2 (whatever the treatment allocated at rando 1)","id":"OG000","title":"Arm A Part 2"},{"description":"All patients randomized to the Daratumumab group at rando 2 even those who didn't receive any treatment dose (whatever the treatment allocated at rando 1).\n\nDaratumumab: Daratumumab 16mg/kg every 8 weeks for 2 years","id":"OG001","title":"Arm B Part 2"}],"paramType":"MEDIAN","populationDescription":"All participants randomized in the second randomization even if they did not receive any study treatment dose.","reportingStatus":"POSTED","timeFrame":"From the date of second randomization to either progressive disease or death which ever occurred first, with a median follow-up time of 35.4 months (cut-off for analysis was 26 months after the last rando 2 date).","title":"Progression Free Survival (PFS) Post Completion of Maintenance Therapy","type":"PRIMARY","unitOfMeasure":"Months"}